scispace - formally typeset
T

Thomas Eschenhagen

Researcher at University of Hamburg

Publications -  423
Citations -  26282

Thomas Eschenhagen is an academic researcher from University of Hamburg. The author has contributed to research in topics: Heart failure & Myocyte. The author has an hindex of 82, co-authored 381 publications receiving 22986 citations. Previous affiliations of Thomas Eschenhagen include Pierre-and-Marie-Curie University & University of Freiburg.

Papers
More filters
Journal ArticleDOI

Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts

TL;DR: This study provides evidence that large contractile cardiac tissue grafts can be constructed in vitro, can survive after implantation and can support contractile function of infarcted hearts.
Journal ArticleDOI

Tissue Engineering of a Differentiated Cardiac Muscle Construct

TL;DR: It is demonstrated that cardiac myocytes from neonatal rats, when mixed with collagen I and matrix factors, cast in circular molds, and subjected to phasic mechanical stretch, reconstitute ring-shaped EHTs that display important hallmarks of differentiated myocardium.
Journal ArticleDOI

What Is the Role of β-Adrenergic Signaling in Heart Failure?

TL;DR: Clinically, &bgr;-adrenergic antagonists represent the most important advance in heart failure therapy, but it is still debated whether they act by blocking or by resensitizing the &b gr;- adrenergic receptor system.
Journal ArticleDOI

Gene expression of the cardiac Na(+)-Ca2+ exchanger in end-stage human heart failure.

TL;DR: The Na(+)-Ca2+ exchanger gene expression is enhanced in failing human hearts and may, in part, compensate for the depressed SR function with regard to diastolic Ca2+ removal.
Journal ArticleDOI

Three-dimensional reconstitution of embryonic cardiomyocytes in a collagen matrix: a new heart muscle model system.

TL;DR: The utility of this system as a test bed for genetic manipulation was demonstrated by infecting the CMPMs with a recombinant β‐galactosidase‐carrying adenovirus, and transduction efficiency increased from about 5% (MOI 0.1) to about 50% ( MOI 100).